ClinicalTrials.gg

Depressive Disorder, Treatment-Resistant clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 449 studies for Depressive Disorder, Treatment-Resistant across more than 10 countries. 147 are recruiting or about to start. 302 of them are mainly about Depressive Disorder, Treatment-Resistant (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-18.

Status

Completed
179
Recruiting
115
Status unknown
38
Active, not recruiting
30
Not yet recruiting
26
Terminated
25

Phase

Phase 2
93
Phase 3
46
Phase 4
34
Phase 1
33
Early Phase 1
5

Where

United States
205
Canada
76
China
30
Germany
28
United Kingdom
26
France
23

Who develops what

Add Depressive Disorder, Treatment-Resistant to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 6 programs from 6 companies, 5 with this as their studies’ main aim; 2 with a live phase 3 study; 2 primary completions in the next 12 months. Compare ACADIA Pharmaceuticals and Johnson & Johnson here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
BupropionEarlier only
Evidence
  • NCT04971291 · Axsome Therapeutics, Inc. · Phase 2 · comparator · “Bupropion SR” · registered Jul 2021
  • NCT03852160 · Johnson & Johnson · Phase 3 · background · “Bupropion” · registered Feb 2019
  • NCT02741791 · Axsome Therapeutics, Inc. · Phase 3 · comparator · “Bupropion” · registered Apr 2016
GlaxoSmithKline28% of its industry studiesUS: off-patent, 31 generics marketed00 studies

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
desethyloxybutynin☆ Track1 live phase-3 study: NCT07227103NeuroRx, Inc.
EsketamineApproved: US 2019 · EU 2019☆ Track1 live phase-3 study: NCT07716098Johnson & Johnson

The 2 in phase 3 with the nearest primary completion, of 6 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (2)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Aug 2027 est.ACP-211 · ACADIA Pharmaceuticals Inc. · Phase 2 named, not the main aimNCT07284667 ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response — primary endpoint: Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score at Day 28 · 153 enrolled
  • Nov 2027 est.ALTO-207 · Alto Neuroscience · Phase 2 main aimNCT07553637 ALTO-207 in Adults With Treatment-resistant Depression (TRD) — primary endpoint: Change in the MADRS total score · 178 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Depressive Disorder, Treatment-Resistant studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Serotonin receptor agonists 9 open · Antipsychotics 2 open · Inhaled anesthetics 2 open · SSRIs 1 open

Coming up

55studies finish main data collection within a year2 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 115 Depressive Disorder, Treatment-Resistant studies recruiting now, 27 (23%) set no upper age limit and 76 (66%) stop at 75 or younger. 1 (1%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 13 (11%) take healthy volunteers.

Recruiting studies that take each age, of 115
AgeWomenMen
100 (0%)0 (0%)
1895 (83%)95 (83%)
30109 (95%)109 (95%)
40109 (95%)109 (95%)
50108 (94%)108 (94%)
65106 (92%)106 (92%)
7549 (43%)49 (43%)
8535 (30%)35 (30%)

Across all 449 studies, recruiting or not: 65% stop at 75 or younger and 45% at 65; 3% take children; 1% are for women only and <1% for men only; 11% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Depressive Disorder, Treatment-Resistant studies take

Of 50 phase 2 interventional studies under Depressive Disorder, Treatment-Resistant, half reached primary completion within 31 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 141 mo16–59 · 19 studies——
Phase 231 mo17–41 · 50 studies——
Phase 330 mo24–59 · 24 studies——
Phase 438 mo27–59 · 18 studies——
Interventional, no phase50 mo22–88 · 140 studies—42 mo22–88 · 136 studies
Observational47 mo25–65 · 33 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 19, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 449. Browse all 449 → or search them.